China's Biggest Ipo In Years Poses $9Bn Question For Western Banks

goldman sachs, JPMorgan and other western banks have spent months lobbying to work on one of china's biggest-ever stock market listings. syngenta's planned $9 billion (chf8.05 billion) shanghai offering seems like a dream ticket for the banks: a large international company that has existing relationships with global institutions.

but as rising geopolitical tension unravels the commercial ties between the us and china, the banks may not even be able to participate, reflecting the rapidly changing business landscape in the world's second-largest economy.

“we do want to be a part” of the swiss agricultural chemicals company's initial public offering (ipo), said one asia-based banker at a global group. but“we always have the question mark – are we able to eventually work on this or not?”

syngenta's owner for the past six years, state-owned chemchina, is on a us government watchlist of companies with close ties to china's military. global banks are asking lawyers and political consultants if they can or should be part of the listing, yet most have no clear answer.

the syngenta listing“is the embodiment of how difficult it is from a financial services standpoint to succeed in china”, said han lin, china country head at advisory firm the asia group.

“if you can't even do [the ipo of] an established international firm with a long history, what hope is there of participating in local deals?”

this year, foreign banks have been involved in just $297 million worth of new listings in china, or 1.2% of the total – putting them on track for the smallest share of the annual total since they began operating in the country's securities sector in 2009, according to data from dealogic.

the freeze-out has been especially harsh for us banks, which have failed to nab spots on a single mainland chinese ipo in 2023, despite a total of $26 billion being raised this year.

if successful, the syngenta public offering will be the fourth-biggest listing in mainland china.

it has taken years to materialise. chemchina, which pulled off the largest-ever outbound takeover by a chinese company when it purchased syngenta in 2017, tried to list it earlier but was delayed by the coronavirus pandemic.

this year, syngenta dropped plans to list on shanghai's tech-focused star board after the exchange rejected it without explanation.

the company finally got the green light from a shanghai stock exchange listing committee this month to list 20% of the company on the exchange's main board. if syngenta achieves its goal of raising rmb65 billion ($9.1 billion), it would rank as one of the largest listings in china's history, according to dealogic data.

more

switzerland is an attractive place to work and the country needs specialists. but work permits can be hard to come by.

bankers at goldman, jpmorgan, morgan stanley, ubs and hsbc – all of which have mainland investment banking businesses – have been lobbying for roles on the listing, for which a roadshow could begin within weeks, said multiple people with knowledge of the process.

“even given the us-china relationship, we continue to stick to our strategy” of bringing international investors to china, said an executive at one of the banks.

western banks are particularly drawn to the listing because it would position them well to win more business if the company carried out a secondary listing in london, zurich or new york – an option that people close to the company have said is still on the table.

more

MENAFN27062023000210011054ID1106509207